{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T09:14:29Z","timestamp":1782810869309,"version":"3.54.5"},"reference-count":16,"publisher":"Zhejiang University Press","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703612"],"award-info":[{"award-number":["81703612"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["springerlink.com","jzus.zju.edu.cn"],"crossmark-restriction":true},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1631\/jzus.b2000728","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T16:13:29Z","timestamp":1627575209000},"page":"599-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir\/ritonavir and arbidol in rats","COVID-19\u6f5c\u5728\u6cbb\u7597\u836f\u7269\u6d1b\u5339\u90a3\u97e6\/\u5229\u6258\u90a3\u97e6\u548c\u963f\u6bd4\u591a\u5c14\u5728\u5927\u9f20\u4f53\u5185\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u76f8\u4e92\u4f5c\u7528"],"prefix":"10.1631","volume":"22","author":[{"given":"Yunzhen","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjuan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7720-2725","authenticated-orcid":false,"given":"Saiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"issue":"3","key":"533_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jhep.2020.04.006","volume":"73","author":"QX Cai","year":"2020","unstructured":"Cai QX, Huang DL, Yu H, et al., 2020a. COVID-19: abnormal liver function tests. J Hepatol, 73(3):566\u2013574. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.006","journal-title":"J Hepatol"},{"issue":"10","key":"533_CR2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","volume":"6","author":"QX Cai","year":"2020","unstructured":"Cai QX, Yang MH, Liu DJ, et al., 2020b. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing), 6(10):1192\u20131198. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007","journal-title":"Engineering (Beijing)"},{"issue":"19","key":"533_CR3","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang YM, Wen DN, et al., 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 382(19):1787\u20131799. https:\/\/doi.org\/10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"issue":"1","key":"533_CR4","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1016\/j.jinf.2020.03.002","volume":"81","author":"LS Deng","year":"2020","unstructured":"Deng LS, Li CN, Zeng Q, et al., 2020. Arbidol combined with LPV\/r versus LPV\/r alone against corona virus disease 2019: a retrospective cohort study. J Infect, 81(1):E1\u2013E5. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.002","journal-title":"J Infect"},{"issue":"1","key":"533_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"JJ Gao","year":"2020","unstructured":"Gao JJ, Tian ZX, Yang X, 2020. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 14(1):72\u201373. https:\/\/doi.org\/10.5582\/bst.2020.01047","journal-title":"Biosci Trends"},{"issue":"1","key":"533_CR6","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 56(1): 105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","journal-title":"Int J Antimicrob Agents"},{"issue":"24","key":"533_CR7","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, et al., 2020. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med, 382(24):2327\u20132336. https:\/\/doi.org\/10.1056\/NEJMoa2007016","journal-title":"N Engl J Med"},{"issue":"12","key":"533_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1631\/jzus.B2000204","volume":"21","author":"YZ Guo","year":"2020","unstructured":"Guo YZ, Xu KJ, Li YT, et al., 2020. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(12):948\u2013954. https:\/\/doi.org\/10.1631\/jzus.B2000204","journal-title":"J Zhejiang Univ-Sci B (Biomed & Biotechnol)"},{"key":"533_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3389\/fmed.2020.00347","volume":"7","author":"SP Jiang","year":"2020","unstructured":"Jiang SP, Wang RR, Li L, et al., 2020. Liver injury in critically ill and non-critically ill COVID-19 patients: a multicenter, retrospective, observational study. Front Med (Lausanne), 7:347. https:\/\/doi.org\/10.3389\/fmed.2020.00347","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"533_CR10","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1128\/AAC.00943-05","volume":"50","author":"V Jullien","year":"2006","unstructured":"Jullien V, Urien S, Hirt D, et al., 2006. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother, 50(11):3548\u20133555. https:\/\/doi.org\/10.1128\/AAC.00943-05","journal-title":"Antimicrob Agents Chemother"},{"key":"533_CR11","volume-title":"Clinical and research information on drug-induced liver injury: protease inhibitors (HIV)","author":"LiverTox","year":"2012","unstructured":"LiverTox, 2012. Clinical and research information on drug-induced liver injury: protease inhibitors (HIV). Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548893"},{"issue":"8","key":"533_CR12","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1177\/0091270007302564","volume":"47","author":"I Ofotokun","year":"2007","unstructured":"Ofotokun I, Chuck SK, Binongo JN, et al., 2007. Lopinavir\/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol, 47(8):970\u2013977. https:\/\/doi.org\/10.1177\/0091270007302564","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"533_CR13","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1177\/0091270010388650","volume":"51","author":"OC Umeh","year":"2011","unstructured":"Umeh OC, Currier JS, Park JG, et al., 2011. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol, 51(12): 1665\u20131673. https:\/\/doi.org\/10.1177\/0091270010388650","journal-title":"J Clin Pharmacol"},{"issue":"15","key":"533_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/cid\/ciaa272","volume":"71","author":"ZL Wang","year":"2020","unstructured":"Wang ZL, Yang BH, Li QW, et al., 2020. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis, 71 (15):769\u2013777. https:\/\/doi.org\/10.1093\/cid\/ciaa272","journal-title":"Clin Infect Dis"},{"issue":"2","key":"533_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3785\/j.issn.1008-9292.2020.02.02","volume":"49","author":"KJ Xu","year":"2020","unstructured":"Xu KJ, Cai HL, Shen YH, et al., 2020. Management of COVID-19: the Zhejiang experience. J Zhejiang Univ (Med Sci), 49(2):147\u2013157 (in Chinese). https:\/\/doi.org\/10.3785\/j.issn.1008-9292.2020.02.02","journal-title":"J Zhejiang Univ (Med Sci)"},{"issue":"5","key":"533_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","volume":"5","author":"C Zhang","year":"2020","unstructured":"Zhang C, Shi L, Wang FS, 2020. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, 5(5):428\u2013430. https:\/\/doi.org\/10.1016\/S2468-1253(20)30057-1","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2000728.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2000728\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2000728.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T08:20:15Z","timestamp":1629188415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2000728","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"https:\/\/orcid.org\/0000-0001-7720-2725","URL":"http","order":0,"name":"name","label":"Saiping JIANG","group":{"name":"orcid","label":"ORCID"}},{"value":"doi:10.1631\/jzus.B2000204","URL":"http:\/\/www.jzus.zju.edu.cn\/article.php?doi=10.1631\/jzus.B2000204","order":0,"name":"name","label":"Safety of protease inhibitors and Arbidol for...","group":{"name":"name","label":"Similar articles"}},{"value":"2021-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-12","order":2,"name":"crosschecked","label":"Crosschecked","group":{"name":"publication_history","label":"Publication History"}},{"value":"Correspondence","order":0,"name":"content_type","group":{"name":"content_type","label":"Content Type"}},{"value":"\u00a9 Zhejiang University Press 2021","order":0,"name":"copyright","group":{"name":"copyright","label":"Copyright"}}]}}